Physician

Min Yan, M.D.

According to 2025 Medicare claims, Min Yan, M.D. (NPI: 1447499710) practices hematology/oncology in the Oakland-Fremont-Berkeley, CA market, with the plurality of this provider's patient population coming from Alameda, CA. This provider's primary affiliated billing organization is EPIC CARE (NPI: 1780107797; TIN: 821993796) and primary practice location at 94608-2038. Yan is affiliated with the Aledade 147 Hill Physicians MSSP Basic E (ACO ID: A5230), participating under the MSSP model.

Yan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 966 traditional Medicare patients, billed 281,947 HCPCS/CPT codes, and received $5,806,384 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 1,820 prescription claims across 321 beneficiaries totaling $5,513,365 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 48 claims. Open Payments data shows 166 records totaling $7,127. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $540,377 to $5,806,384. Similarly, Part D prescription costs have risen steadily, from $307,585 to $5,513,365. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,610 to $1,995.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	214	65,979	$540,377
2016	316	154,632	$1,536,722
2017	447	143,529	$1,984,613
2018	491	212,440	$2,472,589
2019	539	303,915	$3,534,950
2020	598	247,588	$4,701,517
2021	731	298,459	$4,672,424
2022	676	332,717	$4,626,815
2023	723	231,551	$4,649,550
2024	966	281,947	$5,806,384

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	75	512	$307,585
2016	134	946	$1,099,402
2017	161	1,065	$2,069,418
2018	179	1,156	$2,844,307
2019	183	1,130	$2,990,928
2020	260	1,647	$5,412,292
2021	318	1,936	$5,832,392
2022	340	2,149	$5,767,278
2023	331	2,025	$6,957,558
2024	321	1,820	$5,513,365

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	95	$27,032
2016	24	121	$44,498
2017	N/R	80	$19,460
2018	N/R	55	$7,430
2019	N/R	11	$1,809
2020	N/R	15	$285
2021	N/R	46	$4,003
2022	N/R	65	$2,093
2023	N/R	83	$17,090
2024	N/R	48	$986

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	155	225	$1,855
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	656	1,514	$115
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	222	282	$79
36415	Insertion of needle into vein for collection of blood sample	428	1,470	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	323	986	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	134	4,020	$2,102,021
Alecensa	Alectinib Hcl	24	720	$447,552
Imbruvica	Ibrutinib	24	672	$382,484
Cabometyx	Cabozantinib S-Malate	11	330	$273,561
Nubeqa	Darolutamide	20	600	$258,138

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$572
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	164	$5,857	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$1,270	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Min Yan, M.D.?

Tedicare shows public-source Medicare data for Min Yan, M.D. (NPI 1447499710), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Min Yan, M.D. have ACO affiliation data?

Min Yan, M.D. is shown with ACO affiliation data for Aledade 147 Hill Physicians MSSP Basic E (MSSP, ACO ID A5230).

What billing organization is linked to Min Yan, M.D.?

Min Yan, M.D. is linked to EPIC CARE (billing NPI 1780107797) in the available physician profile data.

Does Min Yan, M.D. have Open Payments data?

Min Yan, M.D. has 166 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.